| Year |
Citation |
Score |
| 2022 |
Agyemang K, Johansen AM, Barker GW, Pennison MJ, Sheffield K, Jimenez H, Blackman C, Sharma S, Fordjour PA, Singh R, Cook KL, Lin HK, Zhang W, Lo HW, Watabe K, ... ... Pasche B, et al. TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects. Npj Breast Cancer. 8: 84. PMID 35853889 DOI: 10.1038/s41523-022-00446-6 |
0.466 |
|
| 2021 |
Sirkisoon SR, Carpenter RL, Rimkus T, Doheny D, Zhu D, Aguayo NR, Xing F, Chan M, Ruiz J, Metheny-Barlow LJ, Strowd R, Lin J, Regua AT, Arrigo A, Anguelov M, ... Pasche B, et al. Correction: TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene. PMID 33654200 DOI: 10.1038/s41388-020-01620-5 |
0.358 |
|
| 2020 |
Cai Z, Li CF, Han F, Liu C, Zhang A, Hsu CC, Peng D, Zhang X, Jin G, Rezaeian AH, Wang G, Zhang W, Pan BS, Wang CY, Wang YH, ... ... Pasche B, et al. Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis. Molecular Cell. PMID 33022274 DOI: 10.1016/j.molcel.2020.09.018 |
0.328 |
|
| 2020 |
Mehraein-Ghomi F, Liu L, Topaloglu U, Winkfield K, Kelly M, Pasche B, Zhang W. Abstract C002: Dysregulation of fatty acid metabolism by TP53 mutations underlies more aggressive endometrial cancers in African American women Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-C002 |
0.317 |
|
| 2020 |
Liu L, Mehraein-Ghomi F, Forbes E, Topaloglu U, Petty WJ, Grant S, Ruiz J, Foley KL, Winkfield K, Pasche B, Zhang W. Abstract C001: TP53 mutations reprogram fatty acid metabolism and tumor microenvironment in African American patients with non-small cell lung cancer Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-C001 |
0.347 |
|
| 2019 |
Sirkisoon SR, Carpenter RL, Rimkus T, Doheny D, Zhu D, Aguayo NR, Xing F, Chan M, Ruiz J, Metheny-Barlow LJ, Strowd R, Lin J, Regua AT, Arrigo A, Anguelov M, ... Pasche B, et al. TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene. PMID 31462709 DOI: 10.1038/S41388-019-0959-3 |
0.459 |
|
| 2019 |
Sharma S, Wu SY, Jimenez H, Xing F, Zhu D, Liu Y, Wu K, Tyagi A, Zhao D, Lo HW, Metheny-Barlow L, Sun P, Bourland JD, Chan MD, Thomas A, ... ... Pasche B, et al. Ca and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF. Ebiomedicine. PMID 31129098 DOI: 10.1016/J.Ebiom.2019.05.038 |
0.422 |
|
| 2019 |
Dohm A, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, et al. Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. The International Journal of Biological Markers. 1724600818803104. PMID 30854931 DOI: 10.1177/1724600818803104 |
0.353 |
|
| 2019 |
Lima CMSPR, Alistar AT, Desnoyers RJ, Sorscher S, Yacoub GH, Dressler EVM, Pardee TS, Grant SC, Luther S, Butler D, Ogburn O, Strickland K, Pasche B. A phase I clinical trial of fluorouracil (5-FU) + devimistat (CPI-613) combination in previously treated patients (pts) with metastatic colorectal cancer (MCR). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E15054 |
0.325 |
|
| 2019 |
Song Q, Hawkins GA, Wudel L, Chou P, Forbes E, Pullikuth AK, Liu L, Jin G, Craddock L, Topaloglu U, Kucera G, O’Neill S, Levine EA, Sun P, Watabe K, ... ... Pasche B, et al. Abstract 3391: Dissecting intratumoral cell-cell interactions in myeloid reprogramming by single cell RNA-seq Cancer Research. 79: 3391-3391. DOI: 10.1158/1538-7445.Am2019-3391 |
0.327 |
|
| 2019 |
Liu L, Ahmed T, Petty WJ, Grant S, Ruiz J, Lycan TW, Topaloglu U, Chou P, Miller LD, Hawkins GA, Alexander-Miller MA, O’Neill SS, Powell BL, D’Agostino RB, Munden RF, ... Pasche B, et al. Abstract 3138: SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: A multi-cohort analysis Cancer Research. 79: 3138-3138. DOI: 10.1158/1538-7445.Am2019-3138 |
0.322 |
|
| 2018 |
Shenker RF, Hughes RT, McTyre ER, Lanier C, Lo HW, Metheny-Barlow L, Su J, Thomas A, Brown DR, Avery T, Pasche B, Cramer CK, Laxton AW, Tatter SB, Watabe K, et al. Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. Journal of Radiosurgery and Sbrt. 5: 277-283. PMID 30538888 DOI: 10.1016/J.Ijrobp.2018.07.926 |
0.408 |
|
| 2018 |
Li X, Pasche B, Zhang W, Chen K. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. Jama Oncology. PMID 30098163 DOI: 10.1001/Jamaoncol.2018.2805 |
0.366 |
|
| 2018 |
Liu L, Ruiz J, O'Neill SS, Grant SC, Petty WJ, Yang M, Chen K, Topaloglu U, Pasche B, Zhang W. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Molecular Cancer. 17: 81. PMID 29650000 DOI: 10.1186/S12943-018-0832-Y |
0.316 |
|
| 2018 |
Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, ... ... Pasche B, et al. Use of non-ionizing electromagnetic fields for the treatment of cancer. Frontiers in Bioscience (Landmark Edition). 23: 284-297. PMID 28930547 DOI: 10.2741/4591 |
0.418 |
|
| 2018 |
Jimenez H, Wang M, Zimmerman JW, Pennison MJ, Sharma S, Brezovich I, Absher D, Myers RM, DeYoung BR, Caudell D, Godwin D, Ghanekar A, Miller LD, Capstick M, Kuster N, ... ... Pasche B, et al. Amplitude-modulated radiofrequency electromagnetic fields target hepatocellular carcinoma stem cells through activation of Cav 3.2 T-type calcium channels. Journal of Clinical Oncology. 36: 332-332. DOI: 10.1200/Jco.2018.36.4_Suppl.332 |
0.303 |
|
| 2017 |
Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, et al. Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget. 8: 73947-73963. PMID 29088759 DOI: 10.18632/Oncotarget.18166 |
0.385 |
|
| 2017 |
Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, ... ... Pasche B, et al. Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. Theranostics. 7: 2914-2923. PMID 28824725 DOI: 10.7150/Thno.20355 |
0.431 |
|
| 2017 |
Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, et al. Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget. PMID 28598816 DOI: 10.18632/oncotarget.18166 |
0.385 |
|
| 2017 |
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, ... ... Pasche B, et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. The Lancet. Oncology. PMID 28495639 DOI: 10.1016/S1470-2045(17)30314-5 |
0.357 |
|
| 2017 |
Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, ... ... Pasche B, et al. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. Journal of Hematology & Oncology. 10: 100. PMID 28472989 DOI: 10.1186/S13045-017-0468-1 |
0.311 |
|
| 2017 |
Alistar AT, Pasche B, Morris B, Desnoyer R, D'Agostino R. Anti-mitochondrial therapy in bile duct cancer. Journal of Clinical Oncology. 35: e15661-e15661. DOI: 10.1200/Jco.2017.35.15_Suppl.E15661 |
0.331 |
|
| 2017 |
Sharma S, Jimenez H, Xing F, Blackman C, Pasche B, Watabe K. Abstract 5207: Breast cancer-specific amplitude modulated radiofrequency electromagnetic fields (AM RF EMF) inhibits brain metastasis of breast cancer Cancer Research. 77: 5207-5207. DOI: 10.1158/1538-7445.Am2017-5207 |
0.45 |
|
| 2017 |
Pennison MJ, Wang M, Jimenez H, Pasche B. Abstract 1839: TGFBR1*6A mouse model mimics human breast cancer development and progression Cancer Research. 77: 1839-1839. DOI: 10.1158/1538-7445.Am2017-1839 |
0.461 |
|
| 2017 |
Gmeiner WH, Dominijanni A, Boyacioglu O, Forsyth S, Skardal A, Pasche B. Abstract 1214: The polymeric fluoropyrimidine F10 is effective towards cell and organoid models of 5-FU-resistant colorectal cancer Cancer Research. 77: 1214-1214. DOI: 10.1158/1538-7445.Am2017-1214 |
0.313 |
|
| 2017 |
Alistar AT, Pasche B, D'Agostino R, Pardee T, Luther S, Desnoyer R. 1733PDNew promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx369.165 |
0.322 |
|
| 2017 |
Dohm A, Su J, McTyre E, Soike M, Miller L, Petty W, Xing F, Lo H, Metheny-Barlow L, Watabe K, Chan M, Ruiz J, Pasche B. Determination of Tumor Gene Expression in Non–small Cell Lung Cancer Patients Who Develop Brain Metastasis Diagnosis: Analysis of a Prospective Trial International Journal of Radiation Oncology*Biology*Physics. 99: E453. DOI: 10.1016/J.Ijrobp.2017.06.1687 |
0.389 |
|
| 2016 |
Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo HW, Carpenter RL, Metheny-Barlow LJ, Zhou X, Qasem SA, Pasche B, Watabe K. Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Research. PMID 27364556 DOI: 10.1158/0008-5472.Can-15-3541 |
0.343 |
|
| 2016 |
Principe DR, DeCant B, Staudacher J, Vitello D, Mangan RJ, Wayne EA, Mascariñas E, Diaz AM, Bauer J, McKinney RD, Khazaie K, Pasche B, Dawson DW, Munshi HG, Grippo PJ, et al. Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation. Oncotarget. PMID 27270652 DOI: 10.18632/Oncotarget.9830 |
0.386 |
|
| 2016 |
Principe DR, DeCant B, Mascarinas E, Wayne E, Diaz A, Akagi N, Hwang RF, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ. TGFβ signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis. Cancer Research. PMID 26980767 DOI: 10.1158/0008-5472.Can-15-1293 |
0.404 |
|
| 2016 |
Alistar AT, Desnoyers R, D'Agostino RJ, Pasche B. CPI-613 enhances FOLFIRINOX response rate in stage IV pancreatic cancer Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw371.67 |
0.359 |
|
| 2015 |
Pennison MJ, Zeng Q, Buckhaults PJ, Kaklamani VG, Lindor NM, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile RW, Baron JA, Stram DO, Zhang H, Manne U, Edberg JC, ... ... Pasche B, et al. Dual role of TGFBR1 as a modifier of colorectal cancer risk. Journal of Clinical Oncology. 33: 600-600. DOI: 10.1200/Jco.2015.33.3_Suppl.600 |
0.364 |
|
| 2015 |
Jimenez H, Zimmerman JW, D'Agostino R, Yi X, Brezovich I, Wang M, Pennison MJ, Chen D, Kuster N, Costa F, Barbault A, Blackman CF, Pasche B. The anti-proliferative effects of RF EMF amplitude-modulated at tumor specific frequencies and mediation by calcium. Journal of Clinical Oncology. 33: 11079-11079. DOI: 10.1200/Jco.2015.33.15_Suppl.11079 |
0.337 |
|
| 2014 |
Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, ... ... Pasche B, et al. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1326-38. PMID 25190698 DOI: 10.6004/Jnccn.2014.0127 |
0.377 |
|
| 2014 |
Pasche B, Pennison MJ, Jimenez H, Wang M. TGFBR1 and cancer susceptibility. Transactions of the American Clinical and Climatological Association. 125: 300-12. PMID 25125747 |
0.433 |
|
| 2014 |
Pasche B, Wang M, Pennison M, Jimenez H. Prevention and treatment of cancer with aspirin: where do we stand? Seminars in Oncology. 41: 397-401. PMID 25023355 DOI: 10.1053/J.Seminoncol.2014.04.012 |
0.4 |
|
| 2014 |
Pasche B, Grant SC. Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. Jama. 311: 1975-6. PMID 24846033 DOI: 10.1001/Jama.2014.3742 |
0.378 |
|
| 2014 |
Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C, Grippo PJ. TGF-β: duality of function between tumor prevention and carcinogenesis. Journal of the National Cancer Institute. 106: djt369. PMID 24511106 DOI: 10.1093/Jnci/Djt369 |
0.334 |
|
| 2014 |
Liu NN, Xi Y, Callaghan MU, Fribley A, Moore-Smith L, Zimmerman JW, Pasche B, Zeng Q, Li YL. SMAD4 is a potential prognostic marker in human breast carcinomas. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 35: 641-50. PMID 23975369 DOI: 10.1007/S13277-013-1088-1 |
0.396 |
|
| 2013 |
Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B. Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chinese Journal of Cancer. 32: 573-81. PMID 24206915 DOI: 10.5732/Cjc.013.10177 |
0.427 |
|
| 2013 |
Pasche B. Differential effects of aspirin before and after diagnosis of colorectal cancer. Jama. 309: 2598-9. PMID 23800937 DOI: 10.1001/Jama.2013.6600 |
0.495 |
|
| 2013 |
Chen J, Liu RY, Yang L, Zhao J, Zhao X, Lu D, Yi N, Han B, Chen XF, Zhang K, He J, Lei Z, Zhou Y, Pasche B, Li X, et al. A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. Journal of Cancer Research and Clinical Oncology. 139: 231-42. PMID 23052692 DOI: 10.1007/S00432-012-1314-Z |
0.348 |
|
| 2013 |
Henegan C, Moore-Smith L, Yi N, Ahsan H, Whittemore AS, Pasche B. Decreased TGFBR1 signaling and breast cancer. Journal of Clinical Oncology. 31: 1548-1548. DOI: 10.1200/Jco.2013.31.15_Suppl.1548 |
0.515 |
|
| 2013 |
Henegan JC, Moore-Smith L, Yi N, Zhang K, Ahsan H, Whittemore AS, Pasche B, Co-Investigators B. Abstract 4856: Association between breast cancer and constitutively decreasedTGFBR1signaling. Cancer Research. 73: 4856-4856. DOI: 10.1158/1538-7445.Am2013-4856 |
0.508 |
|
| 2012 |
Pasche B. Aspirin--from prevention to targeted therapy. The New England Journal of Medicine. 367: 1650-1. PMID 23094728 DOI: 10.1056/Nejme1210322 |
0.398 |
|
| 2012 |
Liu RY, Song X, Chen P, Lei Z, Miao J, Yi N, Zhang K, Pasche B, Zhang HT. Association between IL6 -174G/C and cancer: A meta-analysis of 105,482 individuals. Experimental and Therapeutic Medicine. 3: 655-664. PMID 22969947 DOI: 10.3892/Etm.2012.454 |
0.39 |
|
| 2012 |
Tuupanen S, Yan J, Turunen M, Gylfe AE, Kaasinen E, Li L, Eng C, Culver DA, Kalady MF, Pennison MJ, Pasche B, Manne U, de la Chapelle A, Hampel H, Henderson BE, et al. Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genetics. 205: 25-33. PMID 22429595 DOI: 10.1016/J.Cancergen.2012.01.005 |
0.388 |
|
| 2012 |
Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N, Costa FP, Barbault A, Pasche B. Cancer cell proliferation is inhibited by specific modulation frequencies. British Journal of Cancer. 106: 307-13. PMID 22134506 DOI: 10.1038/Bjc.2011.523 |
0.384 |
|
| 2012 |
Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N, Costa FP, Barbault A, Pasche B. Abstract 916A: Cancer cell proliferation is inhibited by specific modulation frequencies Cancer Research. 72: 5612-5612. DOI: 10.1158/1538-7445.Am2012-916A |
0.447 |
|
| 2012 |
Pennison MJ, Bellam N, Zimmerman J, Zeng Q, Sadim M, Kaklamani V, Li N, Zhang K, Stram DO, Pasche B. Abstract 4853: Constitutively decreased TGF-β signaling and risk for colorectal cancer Cancer Research. 72: 4853-4853. DOI: 10.1158/1538-7445.Am2012-4853 |
0.492 |
|
| 2012 |
Moore-Smith LD, Manne K, Caldwell C, Frost A, Pasche B. Abstract 1513: Functional analysis ofTGFBR1mutations in breast cancer associated fibroblasts Cancer Research. 72: 1513-1513. DOI: 10.1158/1538-7445.Am2012-1513 |
0.448 |
|
| 2011 |
Pasche B, Absher D. Whole-genome sequencing: a step closer to personalized medicine. Jama. 305: 1596-7. PMID 21505140 DOI: 10.1001/Jama.2011.484 |
0.376 |
|
| 2011 |
Kaklamani V, Yi N, Sadim M, Siziopikou K, Zhang K, Xu Y, Tofilon S, Agarwal S, Pasche B, Mantzoros C. The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. Bmc Medical Genetics. 12: 52. PMID 21489227 DOI: 10.1186/1471-2350-12-52 |
0.396 |
|
| 2011 |
Moore-Smith L, Pasche B. TGFBR1 signaling and breast cancer. Journal of Mammary Gland Biology and Neoplasia. 16: 89-95. PMID 21461994 DOI: 10.1007/S10911-011-9216-2 |
0.529 |
|
| 2011 |
Kaklamani V, Yi N, Zhang K, Sadim M, Offit K, Oddoux C, Ostrer H, Mantzoros C, Pasche B. Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism: Clinical and Experimental. 60: 1234-43. PMID 21397927 DOI: 10.1016/J.Metabol.2011.01.005 |
0.33 |
|
| 2011 |
Yi N, Kaklamani VG, Pasche B. Bayesian analysis of genetic interactions in case-control studies, with application to adiponectin genes and colorectal cancer risk. Annals of Human Genetics. 75: 90-104. PMID 20846215 DOI: 10.1111/J.1469-1809.2010.00605.X |
0.332 |
|
| 2011 |
McNutt RA, Pasche B, Fontanarosa PB. The 2011 Cancer Theme Issue: Call for Papers Jama. 305: 199-199. DOI: 10.1001/Jama.2010.1973 |
0.433 |
|
| 2010 |
Pasche B. Cancer genetics. Introduction. Cancer Treatment and Research. 155: xi-xii. PMID 20698080 DOI: 10.1007/978-1-4419-6033-7 |
0.432 |
|
| 2010 |
Bellam N, Pasche B. Tgf-beta signaling alterations and colon cancer. Cancer Treatment and Research. 155: 85-103. PMID 20517689 DOI: 10.1007/978-1-4419-6033-7_5 |
0.51 |
|
| 2010 |
Pasche B, Wisinski KB, Sadim M, Kaklamani V, Pennison MJ, Zeng Q, Bellam N, Zimmerman J, Yi N, Zhang K, Baron J, Stram DO, Hayes MG. Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs. Journal of Experimental & Clinical Cancer Research : Cr. 29: 57. PMID 20500843 DOI: 10.1186/1756-9966-29-57 |
0.43 |
|
| 2010 |
Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, ... ... Pasche B, et al. Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network : Jnccn. 8: 562-94. PMID 20495085 DOI: 10.6004/Jnccn.2010.0043 |
0.327 |
|
| 2010 |
Pasche B, Yi N. Candidate gene association studies: successes and failures. Current Opinion in Genetics & Development. 20: 257-61. PMID 20417090 DOI: 10.1016/J.Gde.2010.03.006 |
0.475 |
|
| 2010 |
Pasche B, McNutt RA, Fontanarosa PB. Caring for patients with cancer. Jama. 303: 1094-5. PMID 20233832 DOI: 10.1001/Jama.2010.285 |
0.461 |
|
| 2010 |
Adrian K, Strouch M, Zeng Q, Barron M, Cheon E, Honasage A, Xu Y, Phukan S, Sadim M, Bentrem D, Pasche B, Grippo P. Abstract 3144:Tgfbr1haploinsufficiency inhibits the development of murine mutantKras-induced pancreatic precancer Cancer Research. 70: 3144-3144. DOI: 10.1158/1538-7445.Am10-3144 |
0.386 |
|
| 2009 |
Costa FP, de Oliveira AC, Meirelles R, Machado MM, Surjan R, Chammas M, Bottger B, Morgan D, Barbault A, Pasche B. Phase II study of intrabuccally-administered amplitude-modulated electromagnetic fields in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e15573. PMID 27962384 DOI: 10.1200/Jco.2009.27.15_Suppl.E15573 |
0.301 |
|
| 2009 |
Lei Z, Liu RY, Zhao J, Liu Z, Jiang X, You W, Chen XF, Liu X, Zhang K, Pasche B, Zhang HT. TGFBR1 haplotypes and risk of non-small-cell lung cancer. Cancer Research. 69: 7046-52. PMID 19690145 DOI: 10.1158/0008-5472.Can-08-4602 |
0.381 |
|
| 2009 |
Pasche B, Myers RM. One step forward toward identification of the genetic signature of glioblastomas. Jama. 302: 325-6. PMID 19602695 DOI: 10.1001/Jama.2009.1023 |
0.402 |
|
| 2009 |
Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B. Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. Journal of Experimental & Clinical Cancer Research : Cr. 28: 51. PMID 19366446 DOI: 10.1186/1756-9966-28-51 |
0.407 |
|
| 2009 |
Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis Nature Reviews. Rheumatology. 5: 200-206. PMID 19337284 DOI: 10.1038/Nrrheum.2009.26 |
0.336 |
|
| 2009 |
Zeng Q, Phukan S, Xu Y, Sadim M, Rosman DS, Pennison M, Liao J, Yang GY, Huang CC, Valle L, Di Cristofano A, de la Chapelle A, Pasche B. Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Research. 69: 678-86. PMID 19147584 DOI: 10.1158/0008-5472.Can-08-3980 |
0.772 |
|
| 2009 |
Rebbeck TR, Antoniou AC, Llopis TC, Nevanlinna H, Aittomäki K, Simard J, Spurdle AB, Couch FJ, Pereira LH, Greene MH, Andrulis IL, Pasche B, Kaklamani V, et al. No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Research and Treatment. 115: 185-92. PMID 18523885 DOI: 10.1007/S10549-008-0064-8 |
0.481 |
|
| 2009 |
McNutt RA, Pasche B, Fontanarosa PB. A Theme Issue on Cancer: Call for Papers Jama. 302: 327-327. DOI: 10.1001/Jama.2009.1065 |
0.468 |
|
| 2008 |
Kaklamani VG, Sadim M, Koumantaki Y, Kaklamanis P, Pasche B. Role of polymorphisms in Adamantiades-Behçet's disease. The Journal of Rheumatology. 35: 2376-8. PMID 18925687 DOI: 10.3899/Jrheum.080676 |
0.373 |
|
| 2008 |
Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA, Ahsan H, Mantzoros C, Pasche B. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. Jama. 300: 1523-31. PMID 18827209 DOI: 10.1001/Jama.300.13.1523 |
0.406 |
|
| 2008 |
Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, Li Z, Zeng Q, Zhang HT, Pennison MJ, Sadim M, Pasche B, Tanner SM, de la Chapelle A. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science (New York, N.Y.). 321: 1361-5. PMID 18703712 DOI: 10.1126/Science.1159397 |
0.424 |
|
| 2008 |
Pasche B. Familial colorectal cancer: a genetics treasure trove for medical discovery. Jama. 299: 2564-5. PMID 18523226 DOI: 10.1001/Jama.299.21.2564 |
0.367 |
|
| 2008 |
Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, Ahsan H, Pasche B, Mantzoros C. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Research. 68: 3178-84. PMID 18451143 DOI: 10.1158/0008-5472.Can-08-0533 |
0.455 |
|
| 2008 |
Rosman DS, Phukan S, Huang CC, Pasche B. TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Research. 68: 1319-28. PMID 18316594 DOI: 10.1158/0008-5472.Can-07-5424 |
0.773 |
|
| 2008 |
Pasche B. Recent advances in breast cancer genetics. Cancer Treatment and Research. 141: 1-10. PMID 18274079 DOI: 10.1007/978-0-387-73161-2_1 |
0.473 |
|
| 2007 |
Pennison M, Pasche B. Targeting transforming growth factor-beta signaling. Current Opinion in Oncology. 19: 579-85. PMID 17906455 DOI: 10.1097/Cco.0B013E3282F0Ad0E |
0.403 |
|
| 2007 |
Bian Y, Knobloch TJ, Sadim M, Kaklamani V, Raji A, Yang GY, Weghorst CM, Pasche B. Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development. Human Molecular Genetics. 16: 3128-35. PMID 17890272 DOI: 10.1093/Hmg/Ddm274 |
0.505 |
|
| 2007 |
Rosman DS, Kaklamani V, Pasche B. New insights into breast cancer genetics and impact on patient management. Current Treatment Options in Oncology. 8: 61-73. PMID 17634833 DOI: 10.1007/S11864-007-0021-5 |
0.773 |
|
| 2007 |
Xu Y, Pasche B. TGF-beta signaling alterations and susceptibility to colorectal cancer. Human Molecular Genetics. 16: R14-20. PMID 17613544 DOI: 10.1093/Hmg/Ddl486 |
0.533 |
|
| 2007 |
Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, ... ... Pasche B, et al. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 105: 221-8. PMID 17245541 DOI: 10.1007/S10549-006-9441-3 |
0.387 |
|
| 2007 |
Pasche B, Barbault A, Bottger B, Bomholt F, Kuster N. A phase I study of therapeutic amplitude-modulated electromagnetic fields (THERABIONIC) in advanced tumors Journal of Clinical Oncology. 25: 14072-14072. DOI: 10.1200/Jco.2007.25.18_Suppl.14072 |
0.362 |
|
| 2006 |
Pasche B. A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. Jama. 295: 2537-8. PMID 16757727 DOI: 10.1001/Jama.295.21.2537 |
0.337 |
|
| 2006 |
Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, ... ... Pasche B, et al. Erratum: Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk (Cancer Research (April 15, 2005) 65 (3454-3461)) Cancer Research. 66. DOI: 10.1158/0008-5472.Can-66-6-Cor |
0.778 |
|
| 2005 |
Pasche B, Knobloch T, Bian Y, Liu J, Kaklamani V, Baddi L, Rosman D, de la Chapelle A, Weghorst C. TGFBR1*6A is somatically acquired at high frequency in cancer and switches TGF-β responses. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9511. PMID 27946718 DOI: 10.1200/Jco.2005.23.16_Suppl.9511 |
0.776 |
|
| 2005 |
Kaklamani V, Pasche B. Transforming Growth Factor Beta and breast cancer. Cancer Treatment and Research. 126: 129-56. PMID 16209065 DOI: 10.1007/0-387-24361-5_6 |
0.455 |
|
| 2005 |
Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, Baddi L, Siddiqui FS, Frankel W, Prior TW, Schuller DE, Agrawal A, Lang J, Dolan ME, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. Jama. 294: 1634-46. PMID 16204663 DOI: 10.1001/Jama.294.13.1634 |
0.797 |
|
| 2005 |
Bian Y, Caldes T, Wijnen J, Franken P, Vasen H, Kaklamani V, Nafa K, Peterlongo P, Ellis N, Baron JA, Burn J, Moeslein G, Morrison PJ, Chen Y, Ahsan H, ... ... Pasche B, et al. TGFBR1*6A may contribute to hereditary colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3074-8. PMID 15860866 DOI: 10.1200/Jco.2005.00.281 |
0.515 |
|
| 2005 |
Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, ... ... Pasche B, et al. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Research. 65: 3454-61. PMID 15833881 DOI: 10.1158/0008-5472.Can-04-2961 |
0.786 |
|
| 2005 |
Suarez BK, Pal P, Jin CH, Kaushal R, Sun G, Jin L, Pasche B, Deka R, Catalona WJ. TGFBR1*6A is not associated with prostate cancer in men of European ancestry. Prostate Cancer and Prostatic Diseases. 8: 50-3. PMID 15505640 DOI: 10.1038/Sj.Pcan.4500765 |
0.311 |
|
| 2005 |
Kaklamani VG, Oikonomopoulou C, apos O, Keeffe P, Oikonomopoulou P, Sadim M, Pasche B, Argiris A. TGF-beta polymorphisms in head and neck and lung cancer Journal of Clinical Oncology. 23: 9687-9687. DOI: 10.1200/Jco.2005.23.16_Suppl.9687 |
0.398 |
|
| 2004 |
Kaklamani VG, Bian Y, Liu J, Bradley C, Rademaker A, Ahsan H, Offit K, Pasche B. Polymorphisms of the TGF-β pathway and breast cancer risk: A case control study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9548. PMID 28016875 DOI: 10.1200/Jco.2004.22.14_Suppl.9548 |
0.493 |
|
| 2004 |
Kaklamani V, Baddi L, Rosman D, Liu J, Ellis N, Oddoux C, Ostrer H, Chen Y, Ahsan H, Offit K, Pasche B. No major association between TGFBR1*6A and prostate cancer. Bmc Genetics. 5: 28. PMID 15385056 DOI: 10.1186/1471-2156-5-28 |
0.776 |
|
| 2004 |
Kaklamani VG, Pasche B. Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Review of Anticancer Therapy. 4: 649-61. PMID 15270668 DOI: 10.1586/14737140.4.4.649 |
0.491 |
|
| 2004 |
Patel JD, Pasche B, Argiris A. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Critical Reviews in Oncology/Hematology. 50: 175-86. PMID 15182824 DOI: 10.1016/J.Critrevonc.2004.02.004 |
0.372 |
|
| 2004 |
Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, Ellis N, Offit K, Caldes T, Reiss M, Zheng T. TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 756-8. PMID 14966109 DOI: 10.1200/Jco.2004.99.271 |
0.446 |
|
| 2004 |
Pasche B, Serhan CN. Is C-reactive protein an inflammation opsonin that signals colon cancer risk? Jama. 291: 623-4. PMID 14762043 DOI: 10.1001/Jama.291.5.623 |
0.437 |
|
| 2003 |
Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 3236-43. PMID 12947057 DOI: 10.1200/Jco.2003.11.524 |
0.479 |
|
| 2003 |
Bian Y, Kaklamani V, Reich J, Pasche B. TGF-beta signaling alterations in cancer. Cancer Treatment and Research. 115: 73-94. PMID 12613193 DOI: 10.1007/0-306-48158-8_3 |
0.45 |
|
| 2002 |
Pasche B, Mulcahy M, Benson AB. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Practice & Research. Clinical Gastroenterology. 16: 331-45. PMID 11969242 DOI: 10.1053/Bega.2002.0289 |
0.44 |
|
| 2001 |
Pasche B. Role of transforming growth factor beta in cancer. Journal of Cellular Physiology. 186: 153-68. PMID 11169452 DOI: 10.1002/1097-4652(200002)186:2<153::Aid-Jcp1016>3.0.Co;2-J |
0.475 |
|
| Show low-probability matches. |